AFFiRiS GmbH alzheimers vaccine progress In the medical phase I trial AFF001.

AFFiRiS GmbH alzheimer’s vaccine progress In the medical phase I trial AFF001, AFFiRiS GmbH has recruited the 24 Alzheimer sufferers planned for this trial today. The trial aims to investigate the tolerability and safety of an innovative Alzheimer’s vaccine http://sildenafilca.org . In the trial, all patients have now been vaccinated at least once and have up to now tolerated the vaccine very well. The treatment provides for four vaccinations administered at regular monthly intervals and is due to be fully completed by this October.